Skip to main content

AlphaLISA Human BMP-9 Detection Kit, 100 Assay Points

The AlphaLISA® immunoassay kit for human BMP-9 enables the quantitative determination of human Bone Morphogenetic Protein 9 (BMP-9) in serum, buffered solution, and cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps).

For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Part Number: AL3013HV
Unit Size: 100 Assay Points
Part Number: AL3013C
Unit Size: 500 Assay Points
Part Number: AL3013F
Unit Size: 5,000 Assay Points
  • Formats:

    • Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
    • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
    • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

    Features:

    • No-wash steps, no separation steps
    • ELISA alternative technology
    • Sensitive detection
    • Broad sample compatibility
    • Small sample volume
    • Results in less than 3 hours
    • Half the time of an ELISA assay

    Bone Morphogenetic Protein 9 (BMP-9), also known as growth differentiation factor 2 (GDF2), is a protein of the transforming growth factor beta superfamily. It contains an N-terminal TGF-beta-like pro-peptide (prodomain) (residues 56–257) and a C-terminal transforming growth factor beta superfamily domain (325–428). BMP-9 is expressed by nonparenchymal cells in the liver and secreted as a homodimer. It is involved in a number of physiologic events, including induction of orthotopic bone formation, glucose homeostasis, iron homeostasis and the inhibition of angiogenesis. Mutations in BMP-9 have been identified in patients with a vascular disorder phenotypically overlapping with hereditary hemorrhagic telangiectasia.

    AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

  • Application
    Protein Analysis & Detection
    Assay Points
    100
    Assay Target Class
    Biomarker
    Protein
    Automation Compatible
    Yes
    Brand
    AlphaLISA
    Detection Method
    Alpha
    Experimental Type
    In vitro
    Format
    Microplates
    Therapeutic Area
    Oncology
    Unit Size
    100 Assay Points